A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors - Trial NCT01631279
Access comprehensive clinical trial information for NCT01631279 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Proacta, Incorporated and is currently Terminated. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 33 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Proacta, Incorporated
Timeline & Enrollment
Early Phase 1
Aug 01, 2012
Aug 01, 2015
Primary Outcome
Determine the Maximum Tolerated Dose (MTD) of PR610 for Both a 1-hour and a 24-hour Weekly IV Infusion,Determine the Dose-Limiting Toxicity (DLT) of PR610 for Both a 1-hour and a 24-hour Weekly IV Infusion
Summary
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting
 Toxicity of the drug to further evaluate safety and antitumor activity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01631279
Non-Device Trial